PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
about
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisCIViC databaseMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveEvaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Clinical applications of PD-L1 bioassays for cancer immunotherapy.Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model.Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.Trial watch: Immune checkpoint blockers for cancer therapy.Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular CarcinomaKeeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in CancerPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New EvidencesThe Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung CancerQ58736062Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung AdenocarcinomaTargeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancerPromising clinical application of ctDNA in evaluating immunotherapy efficacyClinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
P2860
Q26740280-A272FB4D-7736-49B5-80A9-06952A75E3B3Q27612411-096D6C2F-91C4-436A-8E0D-D704CCCAADFAQ28070038-2B8CDB83-95C3-40A5-BD14-F7188D677C44Q31137039-B03BDC68-AD92-4737-8B64-D62802FBFF99Q33702815-C821AE0E-C1EA-44E8-B76C-C0170BF61435Q33738921-F935982B-079F-4336-88C2-585CE321E205Q37121401-7242C871-6D0C-45A7-9941-6733E6C8E00FQ37665660-F762CEFB-279D-47E1-8CA2-B59DED43BC4FQ37702705-0D9D0A7A-8EFA-4F8F-AE39-49256345BE57Q37745995-FFC7DA05-924B-4A33-816B-5F0F37B468C0Q38645803-334C720F-6191-4F21-9573-0C738D5ECF0CQ38730989-C551A1A4-2B65-47BA-BDA0-DEE86FEF2B55Q38774259-683FB3DB-217B-43BC-AAF3-ECD34A3AB9CAQ41037588-C5EFED39-77B2-4EF8-B474-E820F61568F6Q41579669-7AC59A59-F081-4BF8-ACCB-FD8BACAAB8D9Q41632271-05CF0052-223E-44CE-B5F1-FC5BE85D17F4Q42721528-01980FF2-EEA8-48E5-863A-5782DDF3466FQ47262054-0F7865AB-C2EA-4195-B131-4A652F025C5DQ47393365-C29E238B-15F3-4E57-9311-4B014E9B0F04Q48307824-5CDECA13-81AA-46BF-A582-BDCA79797C40Q49962956-77C67FA1-B058-4B68-878F-9D51826786F5Q51416101-9AC26846-AD85-4373-BB0A-7AACA862BEA1Q52803851-7D82E5FF-D402-4413-AC6D-FF2810188146Q54620120-7E8276CB-FA24-47CD-B675-F96C236ADD74Q55082051-3013502C-3418-4A1E-AA65-45C67FD87C17Q55348052-0088CA7D-35C1-4B3D-883C-8F4719D7A658Q55401509-F2D17216-CC31-4844-B96F-CD29D3FEBBBBQ56891008-9551A75E-9BFE-48EA-A4C6-2437B0FB3CBFQ56891212-14D4DA31-4A2B-4B85-BE5F-35244A302793Q57191808-85559BC0-6A55-47A0-B0F0-D9B70A7CAB6FQ57300289-010DE5C3-1E48-4F40-B9B6-1D56E9C58EADQ58736062-4FAB85A9-5EA9-4D2D-92BA-126CB45D7414Q58742661-08B28A51-0200-483F-A2B1-EC74EF53E793Q58783242-F7528B89-01DC-44F0-9091-BDF1650ABE68Q58790057-DAE5ED39-AFA0-42FF-ADE7-4F9946B43BE9Q59126078-6F7983AE-97DD-4194-99C8-DFCD9B0CF3C7
P2860
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@ast
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@en
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@nl
type
label
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@ast
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@en
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@nl
altLabel
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
@en
prefLabel
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@ast
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@en
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@nl
P2093
P2860
P3181
P356
P1433
P1476
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
@en
P2093
Angela Listì
Antonio Russo
Christian Rolfo
Daniele Santini
Francesco Passiglia
Giuseppe Bronte
Giuseppe Cicero
Sergio Rizzo
Viviana Bazan
P2860
P304
19738-19747
P3181
P356
10.18632/ONCOTARGET.7582
P407
P577
2016-04-12T00:00:00Z